Peptide Tier List 2026: Ranking All PEPTIGRID Peptides by Risk-to-Reward

Why Most Peptide Content Refuses to Have Opinions

Read enough peptide research content and you'll notice a pattern: every compound is described as "promising," every side-effect profile is "generally well-tolerated," and nobody ever says one peptide is better than another for anything. It's a sea of hedged language designed to avoid being wrong by saying nothing useful.

This is fine for regulatory compliance. It's useless for a researcher trying to decide where to start, what to stack, or how to allocate a limited research budget.

This tier list is opinionated. It will be wrong for some specific research contexts. That's fine - a ranked opinion you can push back on is more useful than neutral mush that says nothing.

How We Ranked: The Three Criteria

• Evidence strength: Volume and quality of published research. Human data ranks higher than animal-only. RCT data ranks higher than observational.
• Side-effect profile: How demanding is the safety monitoring required? How severe and how common are adverse effects at research-relevant doses?
• Beginner accessibility: How much can go wrong in handling, dosing, and administration? How forgiving is the compound to protocol variation?

Higher tier = better risk-to-reward across these three factors. A C-tier compound might outperform an S-tier compound at a specific research question. Tier reflects overall research utility, not ceiling potential.

S Tier - High Evidence, Low Risk, Clear Use Case

BPC-157

The closest thing to a research workhorse in the peptide space. Extensive animal literature, consistent outcomes across multiple injury and gut-health models, exceptionally benign safety profile, and flexible administration routes. The evidence base is animal-heavy, but the volume and consistency is unmatched. For a researcher starting out, BPC-157 is the first peptide to understand.

GHK-Cu

Copper peptide with a genuinely impressive body of evidence across wound healing, collagen synthesis, anti-inflammatory signalling, and hair follicle research. Topical and subcutaneous routes both have published data. Side-effect profile is minimal. One of the few peptides where the mechanism is understood well enough to make specific, testable predictions.

A Tier - Strong Evidence, Manageable Complexity

TB-500

Strong evidence in tissue repair and anti-inflammatory research, with a well-documented synergy with BPC-157 for musculoskeletal endpoints. Drops from S to A primarily because its mechanism overlaps with BPC-157 in ways that make it harder to isolate specific effects, and because it's more expensive per research cycle.

Ipamorelin

The most selective GHRP available. Stimulates GH release without meaningfully affecting cortisol or prolactin. The selectivity simplifies research design considerably. Drops from S primarily because its utility is narrower - GH secretagogue pathway specifically - rather than the broad tissue-level effects of BPC-157 or GHK-Cu.

Semax

ACTH analogue with meaningful neuroprotective and cognitive research, including human data from Russian clinical studies. Nasal administration makes it uniquely accessible. A-tier rather than S because the Western research base is thinner than it deserves to be, and nasal bioavailability introduces more variability than subcutaneous routes.

B Tier - Promising But Narrower or More Complex

CJC-1295 No DAC

A strong GHRH analog with a short half-life that allows pulsatile GH release. Solid evidence, good tolerability. Sits at B rather than A because its research utility is almost always realised in combination with a GHRP like Ipamorelin - which adds protocol complexity and makes isolating its specific contribution harder.

MOTS-C

One of the most mechanistically fascinating peptides in the catalogue - mitochondria-encoded, with published effects on insulin sensitivity, exercise performance, and longevity pathways. B-tier because the human research base is still thin relative to the animal literature, and optimal dosing protocols are still being established. High ceiling. Genuinely novel biology.

C Tier - High Ceiling, High Demand on the Researcher

Retatrutide

C-tier is not a knock on efficacy - Retatrutide has published the highest weight-reduction numbers of any peptide in the catalogue. It lands here because the triple-agonist mechanism (GLP-1R + GIPR + GCGR) demands more from the researcher: careful metabolic monitoring, rigorous titration protocols, and the ability to isolate effects across three receptor pathways simultaneously.

Tesamorelin

The only FDA-approved GHRH analog in the catalogue, which sounds like an argument for a higher tier - but FDA approval is for a specific indication (HIV-associated lipodystrophy) that's narrow relative to general research applications. Outside that indication, the evidence base is thinner than its regulatory status implies, and the cost per research cycle is higher than comparable GHRH analogs.

The Honest Summary

If you're designing your first peptide research protocol, start in S-tier: BPC-157 for repair and gut-health endpoints, GHK-Cu for collagen and wound healing. Add A-tier compounds as your research matures. Reserve C-tier for questions that specifically require their complexity.

The tier list will shift as new research is published. MOTS-C in particular is likely to climb as the human data catches up to the animal literature.